Destiny Pharma plc (“Destiny Pharma” or “the Company”) Expansion of clinical pipeline New XF-73 skin infection clinical programme planned to start in China led by existing partner, China Medical System […]
Thursday September 9, 2021
Interim results for the 6 months ended 30 June 2021
Destiny Pharma today announced its interim results for the 6 months ended 30 June 2021, which can be found here.